SGLT2 Inhibitors and Cardiovascular Outcomes: Do They Differ or There is a Class Effect? New Insights from the EMPA-REG OUTCOME trial and the CVD-REAL Study

被引：9

作者：

Kyriakos, Georgios ^{[1
]}

Quiles-Sanchez, Lourdes, V ^{[2
]}

Garmpi, Anna ^{[3
]}

Farmaki, Paraskevi ^{[4
]}

Kyre, Konstantina ^{[5
]}

Savvanis, Spyridon ^{[6
]}

Antoniou, Vasileios K. ^{[7
]}

Memi, Eleni ^{[8
]}

机构：

[1] Hosp Gen Univ Santa Lucia, Secc Endocrinol & Nutr, Cartagena, Spain

[2] Ctr Salud Jesus Marin, Murcia, Spain

[3] Natl & Kapodistrian Univ Athens, Laiko Gen Hosp, Med Sch, Internal Med Dept, Athens, Greece

[4] Natl & Kapodistrian Univ Athens, Aghia Sophia Childrens Hosp, Dept Pediat 1, Med Sch, Athens, Greece

[5] KAT Gen Hosp, Internal Med Dept, Athens, Greece

[6] Gen Hosp Athens Elpis, Dept Internal Med, Athens, Greece

[7] St Savvas Anticanc Hosp, Breast Surg Clin, Athens, Greece

[8] Ethnikon & Kapodistrian Univ Athens, Aretaieion Univ Hosp, Med Sch Athens, Unit Endocrinol Diabet Mellitus & Metab, Athens, Greece

来源：

CURRENT CARDIOLOGY REVIEWS | 2020年 / 16卷 / 04期

关键词：

SGLT2; inhibitors; T2DM; diabetes type 2 mellitus; EMPA-REG OUTCOME trial; CVD-REAL study; class effect; cardiovascular events; GLUCOSE COTRANSPORTER-2 INHIBITORS; HEART-FAILURE; DIABETES-MELLITUS; LOWERING DRUGS; EMPAGLIFLOZIN; RISK; MORTALITY; CANAGLIFLOZIN; SAFETY; DEATH;

D O I：

10.2174/1573403X15666190730094215

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

A new group of hypoglycemic drugs has been used to treat diabetes type 2. This group is active sodium glucose co-transporter (SGLT2) or SGLT2 inhibitors. It has been shown that besides the treatment of diabetes, this drug class is responsible for the mildness of the cardiovascular events shown in patients with diabetes type 2. However, there is an intriguing question regarding the range of SGLT2 inhibitors and if there is a difference between them or if there is a class effect among their results. EMPA-REG OUTCOME trial and the CVD-study are used to answer this question. Additional information from the DECLARE-TIMI 58 and Dapa-HF trials is studied.

引用

页码：258 / 265

页数：8

共 50 条

[31] Defining the potential "real-world" impact of the EMPA-REG OUTCOME trial on improving cardiovascular outcomes: observations from the Diabetes Collaborative Registry (DCR)
Arnold, S. V.
Inzucchi, S. E.
Maddox, T. M.
Tang, F.
McGuire, D. K.
Mehta, S. N.
Goyal, A.
Sperling, L. S.
Einhom, D.
Wong, N. D.
Kosiborod, M.
DIABETOLOGIA, 2016, 59 : S347 - S348
[32] Empagliflozin reduced long-term HbA1c variability and cardiovascular death: insights from the EMPA-REG OUTCOME trial
Antonio Ceriello
Anne Pernille Ofstad
Isabella Zwiener
Stefan Kaspers
Jyothis George
Antonio Nicolucci
Cardiovascular Diabetology, 19
[33] Empagliflozin reduced long-term HbA1c variability and cardiovascular death: insights from the EMPA-REG OUTCOME trial
Ceriello, Antonio
Ofstad, Anne Pernille
Zwiener, Isabella
Kaspers, Stefan
George, Jyothis
Nicolucci, Antonio
CARDIOVASCULAR DIABETOLOGY, 2020, 19 (01)
[34] Effects of empagliflozin on insulin initiation or intensification in patients with type 2 diabetes and cardiovascular disease: Findings from the EMPA-REG OUTCOME trial
Vaduganathan, Muthiah
Inzucchi, Silvio E.
Sattar, Naveed
Fitchett, David H.
Ofstad, Anne Pernille
Brueckmann, Martina
George, Jyothis T.
Verma, Subodh
Mattheus, Michaela
Wanner, Christoph
Zinman, Bernard
Butler, Javed
DIABETES OBESITY & METABOLISM, 2021, 23 (12): : 2775 - 2784
[35] An exploration of the heterogeneity in effects of SGLT2 inhibition on cardiovascular and all-cause mortality in the EMPA-REG OUTCOME, CANVAS Program, DECLARE-TIMI 58, and CREDENCE trials
Yu, Jie
Zhou, Zien
Mahaffey, Kenneth W.
Matthews, David R.
Neuen, Brendon L.
Heerspink, Hiddo J. L.
Jardine, Meg J.
Li, JingWei
Perkovic, Vlado
Neal, Bruce
Arnott, Clare
INTERNATIONAL JOURNAL OF CARDIOLOGY, 2021, 324 : 165 - 172
[36] Effects of empagliflozin on cardiorenal outcomes in patients with type 2 diabetes and proteinuric diabetic kidney disease: insights from EMPA-REG OUTCOME
Wanner, Christoph
Zinman, Bernard
von Eynatten, Maximilian
Koitka-Weber, Audrey
Zwiener, Isabella
Hauske, Sibylle J.
DIABETES-METABOLISM RESEARCH AND REVIEWS, 2019, 35
[37] Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs The CVD-REAL 2 Study
Kosiborod, Mikhail
Lam, Carolyn S. P.
Kohsaka, Shun
Kim, Dae Jung
Karasik, Avraham
Shaw, Jonathan
Tangri, Navdeep
Goh, Su-Yen
Thuresson, Marcus
Chen, Hungta
Surmont, Filip
Hammar, Niklas
Fenici, Peter
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2018, 71 (23) : 2628 - 2639
[38] Empagliflozin and kidney outcomes in Asian patients with type 2 diabetes and established cardiovascular disease: Results from the EMPA-REG OUTCOMEA® trial
Kadowaki, Takashi
Nangaku, Masaomi
Hantel, Stefan
Okamura, Tomoo
von Eynatten, Maximilian
Wanner, Christoph
Koitka-Weber, Audrey
JOURNAL OF DIABETES INVESTIGATION, 2019, 10 (03) : 760 - 770
[39] EMPAGLIFLOZIN AND PROGRESSION OF CHRONIC KIDNEY DISEASE IN TYPE 2 DIABETES COMPLICATED BY NEPHROTIC-RANGE PROTEINURIA: INSIGHTS FROM THE EMPA-REG OUTCOME® TRIAL
Ruggenenti, Piero
Inzucchi, Silvio
Zinman, Bernard
Hantel, Stefan
Koitka-Weber, Audrey
von Eynatten, Maximilian
Wanner, Christoph
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2018, 33 : 487 - 487
[40] Short-Term Changes in Albuminuria and Risk of Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus: A Post Hoc Analysis of the EMPA-REG OUTCOME Trial
Waijer, Simke W.
Xie, Di
Inzucchi, Silvio E.
Zinman, Bernard
Koitka-Weber, Audrey
Mattheus, Michaela
von Eynatten, Maximillian
Inker, Lesley A.
Wanner, Christoph
Heerspink, Hiddo J. L.
JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2020, 9 (18):

← 1 2 3 4 5 →